相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors
D. D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
The genesis and evolution of high-grade serous ovarian cancer
David D. L. Bowtell
NATURE REVIEWS CANCER (2010)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
Edwin M. Posadas et al.
CANCER (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Kentaro Nakayama et al.
CANCER BIOLOGY & THERAPY (2006)
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
AN Gordon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)